Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039013 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT00039013 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 336 participants.
The verdict
NCT00039013, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (metformin) throughout the study.
Interventions
- DRUG Placebo
- DRUG AC2993
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039013
The ClinicalTrials.gov registry entry for NCT00039013 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00039013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039013 about?
NCT00039013 is a clinical study titled "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin". This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their requ...
What is the current status of trial NCT00039013?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2002-03. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00039013?
The interventions under investigation include: Placebo (DRUG), AC2993 (DRUG).
Who is sponsoring clinical trial NCT00039013?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.